Integrated Insights Business Partner
€36.2k - €67.2k/yr
Junior
Bachelor's
Bratislava, Slovakia
HybridHybrid working options are offered; specific office-day requirements are not stated.
Business & StrategyCorporate Strategy
About the job
Requirements
- A bachelor's degree in Life Sciences, Business, Economics, or Market Research is required.
- One or more years of experience in business analytics or commercial strategy within pharmaceuticals, biotechnology, or healthcare is desirable.
- Exposure to therapeutic-area and/or Value & Access planning, including brand planning, access strategy, and forecasting inputs in a cross-functional environment, is desirable.
- Strong strategic, analytical, and data-insights capabilities across business analytics, competitive intelligence, and forecasting are required.
- Ability to convert data and information into business-relevant insights through strategic, creative, and integrative thinking is required.
- Communication, presentation, and storytelling capabilities, including influencing senior stakeholders, asking relevant questions, and constructively challenging senior business leaders, are required.
- Experience leveraging digital innovation to improve business outcomes and customer value, with technical skills such as SQL, data management, Alteryx, and Power BI, is required.
- An ethical mindset, collaboration orientation, and alignment with Novartis values are required.
Responsibilities
- Act as the primary Integrated Insights contact for assigned therapeutic area(s) and/or Value & Access, consolidating insight and analytics needs from Therapeutic Area, Commercial, and Value & Access stakeholders.
- Translate strategy into clear insights and key business analytics questions.
- Support market research planning and execution for assigned therapeutic area and/or Value & Access scope, including patient journey mapping, segmentation, positioning, market mapping, competitive intelligence, and landscape assessments.
- Integrate internal key performance indicators and external data sources, including claims data, secondary data, competitive intelligence, and the ICE Content & Campaign Performance Dashboard, to generate holistic insights on market, customer, and brand performance.
- Reuse existing international and local research data via knowledge management platforms such as Sherlock before requesting new primary market research, avoiding duplication and inefficiencies.
- Facilitate and serve as a key touchpoint for internationally driven primary market research.
- Coordinate and execute external data acquisition, including panels and syndicated sources, for Commercial and Value & Access needs in accordance with Integrated Insights and Execution Excellence standards.
- Support reporting and data literacy for market, sales, and patient data.
- Serve as the therapeutic-area point of contact for secondary data and insights, including IQVIA products such as RPM, DPM, PharmaScope, DKM, Channel Dynamics, Onco Dynamics, LRx, Xponent, DocSplit, iScore, and Disease Analyzer.
- Prepare and maintain therapeutic-area and Value & Access market assumptions and definitions for forecasting, including epidemiology, uptake, competitor events, and access milestones, in alignment with Integrated Insights frameworks.
- Support the Data, Analytics & Platforms pillar in translating assumptions into dashboards and analytics by co-creating research designs and key performance indicator and Commercial Success Indicator requirements for reporting.
- Partner with Therapeutic Area, Finance, and Value & Access teams to contribute market and access inputs to product and therapeutic-area forecasting and scenario plans, assess growth opportunities, and align assumptions across functions.
- Provide inputs to Field Excellence for incentive target setting.
- Execute payer market research and relevant components of access-oriented studies with Value & Access and Therapeutic Area teams.
- Coordinate external data acquisition and generate customer insights, including Awareness, Trial, Usage, and Performance360 outputs, from primary and secondary research to support Value & Access decisions on value perception and access drivers or barriers.
- Partner with Therapeutic Area, Finance, and Access teams to align access-relevant forecasting assumptions and market outlook across functions.
- Identify and align key performance indicators to measure business performance and inform decision-making.
- Gather and analyze large datasets from various sources to identify trends, patterns, and insights related to financial and market performance, competitors, source of business, customer engagement, and patient numbers.
- Conduct in-depth analysis of market trends, customer behavior, and the competitive landscape to identify opportunities and threats.
- Prepare and deliver comprehensive reports and presentations, translating complex data into actionable insights and recommendations.
- Collaborate with data teams to ensure data accuracy and integrity and identify opportunities for data-product improvement.
Desired Qualifications
- An advanced degree is strongly preferred.
About the company
Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.
Company Size
10,001+
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1970
Get referred to Novartis
See people who can refer or advise you
Simplify's Take
What believers are saying
- Ianalumab won FDA Breakthrough Therapy designation on January 16, 2026.
- Remibrutinib posted positive Phase III data in April 2026 and September 2026.
- The October 2, 2026 Abogen deal adds optionality across autoimmune RNA programs.
What critics are saying
- Entresto generic erosion hits in November 2026 after a September 2026 patent-loss setback.
- Reuters reported two late-stage failures in September 2026 erased nearly $30 billion.
- Novartis faces India pricing pressure over ribociclib; Kerala High Court scrutiny continues.
What makes Novartis unique
- Novartis pairs blockbuster execution with 2026 launches like Rhapsido and Itvisma.
- Its 2026 autoimmune push spans remibrutinib, ianalumab, and Abogen's ABO2203.
- CAS collaboration in September 2026 strengthens Novartis's AI-ready reaction data advantage.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Life Insurance
- Disability Insurance
- 401(k) Retirement Plan
- 401(k) Company Match
- Paid Vacation
- Paid Sick Leave
- Paid Holidays
- Hybrid Work Options